Iguratimod clinical trials
Also written T-614.
How each study uses iguratimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the iguratimod studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 17
Jiangsu Simcere Pharmaceutical Co., Ltd. (5) · Peking University People's Hospital (4) · Qilu Hospital of Shandong University (3) · RenJi Hospital (3) · Peking Union Medical College Hospital (2) · Eisai Co., Ltd. (1) · Nanfang Hospital, Southern Medical University (1) · Xuzhou Medical University (1)
Often tested with
Tested in the same studies.
Leflunomide (2) · Methotrexate (2) · T 614 (1) · Tofacitinib (1) · Glucocorticoid (1) · Adalimumab (1) · Hydroxychloroquine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test iguratimod.
- Dec 2026Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITPPhase 2 · Peking University People's Hospital
- Jun 2027Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHDPhase 1/2 · Xuzhou Medical University
Studies
Open first, then newest update. How each study uses iguratimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHDRecruitingPhase 1/2Xuzhou Medical UniversityNCT06244628Written as Iguratimod
- Treatment Strategies for IgG4-RD Patients With Superficial Organ InvolvementRecruitingNot applicablePeking Union Medical College HospitalNCT05789030Written as glucocorticoid plus iguratimod
- Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITPNot yet recruitingPhase 2Peking University People's HospitalNCT07057778Written as Iguratimod
- The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's SyndromeRecruitingPhase 4Second Affiliated Hospital, Zhejiang University, School of MedicineNCT04981145Written as Iguratimod Tablets
- Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid ArthritisRecruitingPhase 4Yanfeng HouNCT06146972Written as Iguratimod
- Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid ArthritisNot yet recruitingPhase 4Nanfang Hospital, Southern Medical UniversityNCT05803135Written as Iguratimod combined with Tofacitinib;
- The Clinical Efficacy of Immunomodulators in RA PatientsRecruitingPhase 4Qilu Hospital of Shandong UniversityNCT05626348Written as Iguratimod
- The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RACompletedPhase 4Qilu Hospital of Shandong UniversityNCT04928066Written as Iguratimod
- The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months TreatmentCompletedPhase 4Qilu Hospital of Shandong UniversityNCT03855007Written as Iguratimod
- The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune ThrombocytopeniaStatus unknownPhase 2Peking University People's HospitalNCT05281068Written as Iguratimod
- Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune ThrombocytopeniaStatus unknownPhase 2Peking University People's HospitalNCT05302024Written as Iguratimod
- Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO)Status unknownPhase 2/3Peking University People's HospitalNCT05216757Written as Iguratimod
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to MethotrexateCompletedPhase 3Eisai Co., Ltd.NCT00965757Written as T-614
- A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.Status unknownPhase 2Jiangsu Simcere Pharmaceutical Co., Ltd.NCT04830644Written as Iguratimod
- A Study of Iguratimod in Patients With Active Rheumatoid ArthritisCompletedPhase 4Jiangsu Simcere Pharmaceutical Co., Ltd.NCT01554917Written as Iguratimod
- Iguratimod in Systemic SclerosisStatus unknownNot applicableRenJi HospitalNCT04515706Written as Iguratimod
- The Iguratimod Effect on Lupus Nephritis (IGeLU)Status unknownPhase 2RenJi HospitalNCT02936375Written as Iguratimod
- Iguratimod in Kidney Transplant RecipientsStatus unknownNot applicableThe First Affiliated Hospital with Nanjing Medical UniversityNCT02839941Written as Iguratimod
- Iguratimod as Treatment for Refractory Lupus NephritisStatus unknownNot applicableRenJi HospitalNCT03054545Written as Iguratimod
- Study of Iguratimod in Sjögren's SyndromeStatus unknownPhase 1/2Peking Union Medical College HospitalNCT03023592Written as Iguratimod
See all 23 studies that test iguratimod →
Given beside what is tested · 1 — iguratimod is usual care or a partner of the new treatment
Codes
What other systems call iguratimod · ClinicalTrials.gg INT005072
- MeSH (NLM) C519076iguratimodOne source NLM
- UNII (FDA) 4IHY34Y2NVIGURATIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q13575264iguratimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65886IguratimodOne source FDA
- DrugBank DB12233One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C519076 | iguratimod | One source NLM |
| UNII (FDA) | 4IHY34Y2NV | IGURATIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q13575264 | iguratimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65886 | Iguratimod | One source FDA |
| DrugBank | DB12233 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.